microRNA-323 upregulation promotes prostate cancer growth and docetaxel resistance by repressing p73

Gao, Qiruo; Zheng, Junhua

doi:10.1016/j.biopha.2017.10.040

Cited by 28 publications

(24 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Besides miR-181c, our study also revealed a strong positive correlation between miR-323 expression and HPV16 E7 expression among episomal CaCx cases. There are reports showing miR-323 upregulation in metastatic squamous cell CaCx cases 35 and several studies on prostate cancers 36,37 , which are suggestive of the potential of this microRNA in imparting aggressiveness to such cancers. We also validated this through cell line based in vitro analysis as indicated in Fig.…”

Section: Discussionmentioning

confidence: 92%

Cervical cancer subtypes harbouring integrated and/or episomal HPV16 portray distinct molecular phenotypes based on transcriptome profiling of mRNAs and miRNAs

et al. 2019

View full text Add to dashboard Cite

Heterogeneity in cervical cancers (CaCx) in terms of HPV16 physical status prompted us to investigate the mRNA and miRNA signatures among the different categories of CaCx samples. We performed microarray-based mRNA expression profiling and quantitative real-time PCR-based expression analysis of some prioritised miRNAs implicated in cancer-related pathways among various categories of cervical samples. Such samples included HPV16-positive CaCx cases that harboured either purely integrated HPV16 genomes (integrated) and those that harboured episomal viral genomes, either pure or concomitant with integrated viral genomes (episomal), which were compared with normal cervical samples that were either HPV negative or positive for HPV16. The mRNA expression profile differed characteristically between integrated and episomal CaCx cases for enriched biological pathways. miRNA expression profiles also differed among CaCx cases compared with controls (upregulation—miR-21, miR-16, miR-205, miR-323; downregulation—miR-143, miR-196b, miR-203, miR-34a; progressive upregulation—miR-21 and progressive downregulation—miR-143, miR-34a, miR-196b and miR-203) in the order of HPV-negative controls, HPV16-positive non-malignant samples and HPV16-positive CaCx cases. miR-200a was upregulated in HPV16-positive cervical tissues irrespective of histopathological status. Expression of majority of the predicted target genes was negatively correlated with their corresponding miRNAs, irrespective of the CaCx subtypes. E7 mRNA expression correlated positively with miR-323 expression among episomal cases and miR-203, among integrated cases. miR-181c expression was downregulated only among the episomal CaCx cases and negatively correlated with protein coding transcript of the proliferative target gene, CKS1B of the significantly enriched “G2/M DNA Damage Checkpoint Regulation” pathway among CaCx cases. Thus, the two CaCx subtypes are distinct entities at the molecular level, which could be differentially targeted for therapy. In fact, availability of a small molecule inhibitor of CKS1B, suggests that drugging CKS1B could be a potential avenue of treating the large majority of CaCx cases harbouring episomal HPV16.

show abstract

Section: Discussionmentioning

confidence: 92%

Cervical cancer subtypes harbouring integrated and/or episomal HPV16 portray distinct molecular phenotypes based on transcriptome profiling of mRNAs and miRNAs

et al. 2019

View full text Add to dashboard Cite

show abstract

“…PARP is the downstream effector protein of caspase. Increased cleavage of caspase-3 has been shown to increase the sensitivity of prostate cancer to DTX 27 . In this study, we found that DTX combined with ZD55-IL-24 significantly decreased PARP-1 levels and increased caspase-3 and caspase-8 levels in vitro and in vivo , compared to single treatment.…”

Section: Discussionmentioning

confidence: 99%

Oncolytic Adenovirus Harboring Interleukin-24 Improves Chemotherapy for Advanced Prostate Cancer

Mao¹,

Ding²,

Xu³

et al. 2018

J. Cancer

View full text Add to dashboard Cite

Purpose: Oncolytic adenoviruses emerge as new agents for cancer therapy. This study aimed to investigate the synergistic anti-tumor activity of oncolytic adenovirus armed with IL-24 (ZD55-IL-24) and docetaxel (DTX) on advanced prostate cancer in vitro and in vivo.Methods: DU145 prostate cancer cells or nude mice xenografted with DU145 prostate cancer cells were treated by ZD55-IL-24 and DTX alone or in combination.Results: DTX did not affect ZD55-IL-24 replication and IL-24 expression in DU145 cells. In vitro, the combination of ZD55-IL-24 and DTX showed synergistic inhibitory effects on prostate cancer cell viability and invasion. In vivo, ZD55-IL-24 and DTX synergistically inhibited the growth and activated the apoptosis of DU145 xenografts, accompanied by significantly decreased PARP-1 levels and increased caspase-3 and caspase-8 levels as well as decreased CD31 expression.Conclusion: We reported the synergistic anti-tumor efficacy of ZD55-IL-24 and DTX on prostate cancer. Our results suggest that chemotherapy combined with oncolytic adenovirus mediated gene therapy is a promising strategy for the treatment of advanced prostate cancer.

show abstract

“…It has been shown that IR treated cells secrete exosomes that can be taken up by non-irradiated neighboring cells and induce biological changes via the bystander effect [157,158]. These IR-induced exosomes may promote radioresistance, leading to tumor progression and [150] ZEB1, ZEB2 [128] miR-323-3p p73 [151], AdipoR1 [152] miR-379-5p -miR-409-3p PHC3, RSU1,TUSC1 [153] miR-411-5p -miR-493-5p c-Met, CREB1, EGFR [154] miR-494-3p CXCR4 [155] miR-543 RKIP [156] miR-654-3p AR [74] RT radiotherapy, CIRT carbon ion radiotherapy, PCa prostate cancer, PTEN phosphatase and TENsin homolog, MARCKS myristoylated alanine-rich protein kinase c substrate, ANP32A acid nuclear phosphoprotein 32 family member A, SMARCA4 SWI/SNF related matrix associated actin dependent regulator of chromatin subfamily A member 4, AdipoR1 Adiponectin receptor 1, PHC3 polyhomeotic homolog 3, RSU1 Ras suppressor protein 1, TUSC1 tumor suppressor candidate 1, CREB1 CAMP responsive element binding protein 1, EGFR epidermal growth factor, CXCR4 CXC chemokine receptor 4, RKIP Raf kinase inhibitor protein, AR androgen receptor the formation of a pre-metastatic niche. Previous examples have indeed shown a resistance transfer by exosomes in breast cancer carcinoma [159,160], head and neck cancer [161] and glioblastoma [162].…”

Section: Mirnas In Extracellular Vesiclesmentioning

confidence: 99%

microRNAs identified in prostate cancer: Correlative studies on response to ionizing radiation

et al. 2020

View full text Add to dashboard Cite

As the most frequently diagnosed non-skin cancer in men and a leading cause of cancer-related death, understanding the molecular mechanisms that drive treatment resistance in prostate cancer poses a significant clinical need. Radiotherapy is one of the most widely used treatments for prostate cancer, along with surgery, hormone therapy, and chemotherapy. However, inherent radioresistance of tumor cells can reduce local control and ultimately lead to poor patient outcomes, such as recurrence, metastasis and death. The underlying mechanisms of radioresistance have not been fully elucidated, but it has been suggested that miRNAs play a critical role. miRNAs are small non-coding RNAs that regulate gene expression in every signaling pathway of the cell, with one miRNA often having multiple targets. By fine-tuning gene expression, miRNAs are important players in modulating DNA damage response, cell death, tumor aggression and the tumor microenvironment, and can ultimately affect a tumor's response to radiotherapy. Furthermore, much interest has focused on miRNAs found in biofluids and their potential utility in various clinical applications. In this review, we summarize the current knowledge on miRNA deregulation after irradiation and the associated functional outcomes, with a focus on prostate cancer. In addition, we discuss the utility of circulating miRNAs as non-invasive biomarkers to diagnose, predict response to treatment, and prognosticate patient outcomes.

show abstract

microRNA-323 upregulation promotes prostate cancer growth and docetaxel resistance by repressing p73

Cited by 28 publications

References 21 publications

Cervical cancer subtypes harbouring integrated and/or episomal HPV16 portray distinct molecular phenotypes based on transcriptome profiling of mRNAs and miRNAs

Cervical cancer subtypes harbouring integrated and/or episomal HPV16 portray distinct molecular phenotypes based on transcriptome profiling of mRNAs and miRNAs

Oncolytic Adenovirus Harboring Interleukin-24 Improves Chemotherapy for Advanced Prostate Cancer

microRNAs identified in prostate cancer: Correlative studies on response to ionizing radiation

Contact Info

Product

Resources

About